Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruno Fautrel

Showing results (251-260 of 371) with videos related to

Pageof 38
Sort By:
Rheumatology and Therapy|October 13, 2022
The RA-BE-REAL Multinational, Prospective, Observational Study in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic, or Biologic Disease-Modifying Therapies: a 6-Month Interim AnalysisRieke Alten, Gerd R Burmester, Marco Matucci-Cerinic, et al.
Rheumatology and Therapy|September 27, 2023
Comparative Effectiveness, Time to Discontinuation, and Patient-Reported Outcomes with Baricitinib in Rheumatoid Arthritis: 2-Year Data from the Multinational, Prospective Observational RA-BE-REAL Study in European PatientsRieke Alten, Gerd R Burmester, Marco Matucci-Cerinic, et al.
Joint Bone Spine|March 16, 2025
Diseases associated with anti-centromere protein F (anti-CENP-F) antibodies: Insights from a large cohort studyAlexandre Le Joncour, Jean-Luc Charuel, Sylvain Choquet, et al.
Arthritis Care & Research|September 23, 2018
Detection of Flares by Decrease in Physical Activity, Collected Using Wearable Activity Trackers in Rheumatoid Arthritis or Axial Spondyloarthritis: An Application of Machine Learning Analyses in RheumatologyLaure Gossec, Frédéric Guyard, Didier Leroy, et al.
Seminars in Arthritis and Rheumatism|September 19, 2019
Definition and construct validation of clinically relevant cutoffs on the Flare Assessment in Rheumatoid Arthritis (FLARE-RA) questionnaireElena Myasoedova, Annette De Thurah, Marie-Line Erpelding, et al.
Rheumatology (Oxford, England)|September 2, 2017
Drivers of patient global assessment in patients with rheumatoid arthritis who are close to remission: an analysis of 1588 patientsRicardo J O Ferreira, Maxime Dougados, John R Kirwan, et al.
Journal of Clinical Epidemiology|July 27, 2024
Building a composite score for patient self-report of flare in osteoarthritis: a comparison of methods with the Flare-OA-16 questionnaireFabiana Queiroga, Jonathan Epstein, Marie-Line Erpelding, et al.
BMJ Open|June 17, 2025
Abatacept versus tocilizumab for the treatment of rheumatoid arthritis in TNF inhibitor inadequate responders: study protocol of the SUNSTAR randomised controlled open-label superiority trialTristan Pascart, Bruno Fautrel, Jacques-Eric Gottenberg, et al.
Arthritis Research & Therapy|October 24, 2009
Determining a low disease activity threshold for decision to maintain disease-modifying antirheumatic drug treatment unchanged in rheumatoid arthritis patientsMichel de Bandt, Bruno Fautrel, Jean Francis Maillefert, et al.
Arthritis and Rheumatism|April 1, 2009
Choice of second-line disease-modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: a decision tree for clinical practice based on rheumatologists' preferencesBruno Fautrel, Francis Guillemin, Olivier Meyer, et al.
Pageof 38

Showing results (251-260 of 371) with videos related to

Sort By:
Pageof 38
Rheumatology and Therapy|October 13, 2022
The RA-BE-REAL Multinational, Prospective, Observational Study in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic, or Biologic Disease-Modifying Therapies: a 6-Month Interim AnalysisRieke Alten, Gerd R Burmester, Marco Matucci-Cerinic, et al.
Rheumatology and Therapy|September 27, 2023
Comparative Effectiveness, Time to Discontinuation, and Patient-Reported Outcomes with Baricitinib in Rheumatoid Arthritis: 2-Year Data from the Multinational, Prospective Observational RA-BE-REAL Study in European PatientsRieke Alten, Gerd R Burmester, Marco Matucci-Cerinic, et al.
Joint Bone Spine|March 16, 2025
Diseases associated with anti-centromere protein F (anti-CENP-F) antibodies: Insights from a large cohort studyAlexandre Le Joncour, Jean-Luc Charuel, Sylvain Choquet, et al.
Arthritis Care & Research|September 23, 2018
Detection of Flares by Decrease in Physical Activity, Collected Using Wearable Activity Trackers in Rheumatoid Arthritis or Axial Spondyloarthritis: An Application of Machine Learning Analyses in RheumatologyLaure Gossec, Frédéric Guyard, Didier Leroy, et al.
Seminars in Arthritis and Rheumatism|September 19, 2019
Definition and construct validation of clinically relevant cutoffs on the Flare Assessment in Rheumatoid Arthritis (FLARE-RA) questionnaireElena Myasoedova, Annette De Thurah, Marie-Line Erpelding, et al.
Rheumatology (Oxford, England)|September 2, 2017
Drivers of patient global assessment in patients with rheumatoid arthritis who are close to remission: an analysis of 1588 patientsRicardo J O Ferreira, Maxime Dougados, John R Kirwan, et al.
Journal of Clinical Epidemiology|July 27, 2024
Building a composite score for patient self-report of flare in osteoarthritis: a comparison of methods with the Flare-OA-16 questionnaireFabiana Queiroga, Jonathan Epstein, Marie-Line Erpelding, et al.
BMJ Open|June 17, 2025
Abatacept versus tocilizumab for the treatment of rheumatoid arthritis in TNF inhibitor inadequate responders: study protocol of the SUNSTAR randomised controlled open-label superiority trialTristan Pascart, Bruno Fautrel, Jacques-Eric Gottenberg, et al.
Arthritis Research & Therapy|October 24, 2009
Determining a low disease activity threshold for decision to maintain disease-modifying antirheumatic drug treatment unchanged in rheumatoid arthritis patientsMichel de Bandt, Bruno Fautrel, Jean Francis Maillefert, et al.
Arthritis and Rheumatism|April 1, 2009
Choice of second-line disease-modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: a decision tree for clinical practice based on rheumatologists' preferencesBruno Fautrel, Francis Guillemin, Olivier Meyer, et al.
Pageof 38